{"blog": [], "keywords": [{"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "1", "is_major": "N"}, {"value": "Pfizer Inc", "name": "organizations", "rank": "2", "is_major": "N"}, {"value": "Medivation Inc", "name": "organizations", "rank": "3", "is_major": "N"}, {"value": "Mergers, Acquisitions and Divestitures", "name": "subject", "rank": "4", "is_major": "N"}, {"value": "Astellas Pharma", "name": "organizations", "rank": "5", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/08/23/business/dealbook/the-flaws-in-pfizers-plan-to-acquire-medivation.html", "document_type": "article", "byline": {"person": [{"lastname": "CYRAN", "firstname": "Robert", "role": "reported", "organization": "", "rank": 1}], "original": "By ROBERT CYRAN"}, "type_of_material": "News", "multimedia": [], "section_name": "Business Day", "word_count": "376", "source": "The New York Times", "subsection_name": "DealBook", "lead_paragraph": "A heated auction and back-of-the-envelope math hint that the buyer is overpaying.", "pub_date": "2016-08-23T04:00:00+0000", "news_desk": "Business", "headline": {"kicker": "Breakingviews", "main": "The Flaws in Pfizer\u2019s Plan to Acquire Medivation", "content_kicker": "Breakingviews"}, "print_page": null, "snippet": "A heated auction and back-of-the-envelope math hint that the buyer is overpaying....", "_id": "57bb5b0295d0e021d798203d", "slideshow_credits": null, "abstract": null}